Sep 18, 2015 - TG Therapeutics (TGTX) reached an agreement with the FDA related to a Special Protocol Assessment of a phase III study design for TG-1101 for chronic lymphocytic leukemia.
Sep 18, 2015 - 3M Safety and Graphics Business Group, a part of 3M Company (MMM), recently announced a minority equity investment in StrongArm Technologies Inc., - a company that designs innovative safety products.
Sep 18, 2015 - Eli Lilly and Company (LLY) was a big mover last session, as the company saw its shares rise roughly 7% on the day.
Sep 16, 2015 - GW Pharmaceuticals plc (GWPH) announced encouraging top-line data from an exploratory phase IIa study on cannabidiol in patients suffering from schizophrenia who had previously failed to respond adequately to first-line anti-psychotic medications.
Sep 02, 2015 - Amgen (AMGN) inks deal with Novartis for Alzheimer's disease and migraine; reports positive phase III data on romosozumab.
Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Aug 31, 2015 - Eli Lilly has seen a nice streak of beating earnings estimates at the previous two reports, suggesting it has a nice short-term history of crushing expectations and that it could be a great candidate for another beat
Aug 28, 2015 - Eli Lilly (LLY) announced that the FDA has approved its diabetes drug, Synjardy, for the treatment of patients with type II diabetes.
Aug 27, 2015 - Oncolytics Biotech (ONCY) completed enrolling patients in a phase II study on Reolysin for the treatment of non-small cell lung cancer.
Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.